Description
NEBROOT-AM
Nebivolol 5 mg and S(-) Amlodipine 5 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Nebivolol IP — 5 mg
S(-) Amlodipine IP — 5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
NEBROOT-AM is a scientifically balanced antihypertensive combination of Nebivolol 5 mg and S(-) Amlodipine 5 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the highly selective beta-1 blocking and nitric oxide-mediated vasodilatory effects of Nebivolol with the sustained vasodilatory action of S(-) Amlodipine, resulting in superior antihypertensive efficacy and improved cardiovascular outcomes.
Nebivolol is a third-generation beta-1 selective blocker with additional nitric oxide-mediated vasodilatory properties that helps reduce heart rate, myocardial oxygen demand, and vascular resistance while improving endothelial function. S(-) Amlodipine is the pharmacologically active isomer of amlodipine that provides effective arterial vasodilation with improved efficacy and a lower incidence of peripheral edema compared with conventional racemic amlodipine.
NEBROOT-AM is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, diabetes, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy with heart rate control.
Technical Knowledge of Nebivolol and S(-) Amlodipine
Nebivolol selectively blocks beta-1 adrenergic receptors in the heart and stimulates endothelial nitric oxide release, producing vasodilation, reduced heart rate, decreased myocardial contractility, improved endothelial function, and enhanced vascular compliance.
S(-) Amlodipine selectively inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval.
The combination of Nebivolol and S(-) Amlodipine provides complementary antihypertensive mechanisms with additional cardiovascular and endothelial protective benefits.
Mechanism of Action
Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, stimulates nitric oxide-mediated vasodilation, improves endothelial function, decreases peripheral vascular resistance, and reduces myocardial oxygen demand.
S(-) Amlodipine blocks L-type calcium channels, relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive action.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Reduces heart rate and myocardial workload
Supports cardiovascular protection
Improves endothelial function
Enhances vascular compliance
May reduce the incidence of peripheral edema
Suitable for long-term hypertension management under medical supervision
Clinical Applications
NEBROOT-AM is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Nebivolol and S(-) Amlodipine
Nebivolol is a modern beta-blocker with nitric oxide-mediated vasodilatory activity and excellent metabolic and endothelial profiles. S(-) Amlodipine is the active isomer responsible for the therapeutic antihypertensive effect of amlodipine and is associated with effective blood pressure control and improved tolerability. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control.
Key Facts
Beta-blocker and calcium channel blocker combination therapy
Nebivolol 5 mg for heart rate control and endothelial support
S(-) Amlodipine 5 mg for sustained arterial vasodilation
Provides comprehensive blood pressure and heart rate control
Effective in hypertension with coronary artery disease and diabetes
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
NEBROOT-AM is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose NEBROOT-AM for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Nebivolol 5 mg and S(-) Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
NEBROOT-AM from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nebivolol and S(-) Amlodipine formulation.